Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (161-170 of 205) with videos related to

Pageof 21
Sort By:
Urologic Oncology|February 26, 2013
Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLDSarah A Gallagher, Angela B Smith, Jonathan E Matthews, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable PhenotypeJordan Kardos, Sara E Wobker, Michael E Woods, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerTracy L Rose, Michael R Harrison, Allison M Deal, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Nature Communications|May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancerWolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 GuidelinesAntoine G van der Heijden, Harman Max Bruins, Albert Carrion, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
Pageof 21

Showing results (161-170 of 205) with videos related to

Sort By:
Pageof 21
Urologic Oncology|February 26, 2013
Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLDSarah A Gallagher, Angela B Smith, Jonathan E Matthews, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable PhenotypeJordan Kardos, Sara E Wobker, Michael E Woods, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerTracy L Rose, Michael R Harrison, Allison M Deal, et al.
Bladder Cancer (Amsterdam, Netherlands)|December 31, 2016
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder CancerTracy L Rose, Allison M Deal, Sylvain Ladoire, et al.
Nature Communications|May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancerWolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, et al.
Clinical Genitourinary Cancer|December 3, 2014
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
European Urology|March 21, 2025
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 GuidelinesAntoine G van der Heijden, Harman Max Bruins, Albert Carrion, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
Pageof 21